News – Page 965 – Endpoints News

Capricor to resume dosing in DMD trial — but scarce resources force company to pause enrollment, cut jobs

7 years ago

Eli Lilly silently walks away from a troubled $690M alliance after BTK drug flounders in PhII

7 years ago

To tackle superbug scourge and revive R&D, incentivize FDA antibiotic approvals — drugmakers, health groups urge US ...

7 years ago

MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin — shares rocket higher

7 years ago

Say what? Trump declares a big victory in the war on drug prices — for December, anyhow

7 years ago

A 'disoriented' Pain Therapeutics flips out after FDA rejects appeal on Remoxy

7 years ago

Amgen, Sanofi back a round for real-world evidence platform tech; Daiichi Sankyo's pexidartinib secures speedy FDA ...

7 years ago

Here come the 2019 unicorns: Alector, Gossamer set to launch IPOs donning $1B-plus market caps

7 years ago

The bispecific boom: Genentech pays $120M to tie the knot with Xencor on an IL-15 alliance

7 years ago

After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck

7 years ago

As Herceptin biosimilars eat into Roche sales, Swiss drugmaker makes case for expanded Kadcyla use

7 years ago

In a field littered with failures, positive data prompt speedy US, EU review of AstraZeneca's long-acting RSV drug

7 years ago

Shakeup at the top of FDA’s biosimilars division as Leah Christl departs for Amgen

7 years ago

Flying solo for a change, Sanofi says isatuximab scored an important success in first PhIII myeloma study

7 years ago

Baeuerle-backed Cullinan grows its pipeline of portfolio plays, adopts a new cancer drug with eye to clinical ...

7 years ago

Gilead takes an $820M hit after axing a Kite CAR-T. Are billions more going to be incinerated?

7 years ago

Halozyme scores $30M in cash for its latest alliance; Bernie Sanders takes aim at $375,000 rare disease drug

7 years ago

Keto in a pill? Jim Mellon debuts anti-aging joint venture with the Buck dedicated to inducing ketosis

7 years ago

Peter Diamandis' right hand man Sergey Young wants to reverse aging via his $100M Longevity Vision Fund

7 years ago

'Most feared' activist investor in America has zeroed in on Bristol-Myers Squibb. Is he planning to derail the $74B ...

7 years ago

Evolus celebrates greenlight for Botox rival while Allergan counterattacks with a complaint of stolen trade secrets

7 years ago

Medicxi bankrolls the launch of a pair of biotech twins focused on orexins for narcolepsy and more

7 years ago

GenSight’s second LHON gene therapy PhIII stumbles out of the gate — just like the first time

7 years ago

Alkermes shares take another hit as the FDA shakes its head — again — on a weak case for '5461

7 years ago

First page Previous page 962 963 964965966 967 968 Next page Last page